13 Pharmas Sign Roadmap For Antibiotic Reform – But What Do They Want?
More than 13 global pharma companies, including GlaxoSmithKline, Pfizer and Merck & Co., have agreed a "Roadmap" aimed at relieving the growing antimicrobial resistance crisis worldwide – as well as principles to explore alternative business models and incentives for antibiotic R&D and reimbursement.
You may also be interested in...
Evotec's CEO tells Scrip its pact with Sanofi to develop an infectious disease pipeline could offer a commercially viable approach to battling the global AMR crisis.
The globalized drugs industry needs to play ball and help find a solution to antimicrobial resistance or risk getting blamed for its failure and the resulting world health crisis.
Having suddenly resigned from the UK government, Jim O’Neill says he’s now available to take on a global role, if asked, to promote concrete action on tackling antimicrobial resistance within promised timeframes.